Release time ：2023-06-26
Source：support@yingchitech.com
Scan：769
Visiting time: June 12-16, 2023
With the rapid development of neuromodulation technology, non-invasive neuromodulation technology represented by transcranial magnetic stimulation has been widely used in neuropsychiatric diseases. Among them, deep transcranial magnetic stimulation (DTMS) has significantly improved the magnetic field decay rate, magnetic field penetration depth, and induced electric field area and volume induced in brain tissue.
In order to further promote the clinical application of DTMS in psychiatry and various clinical specialties or departments, and promote the standardization of the use of DTMS by clinicians and rehabilitation therapists in the treatment of mental diseases in clinical practice, Shenzhen Yingchi Technology Co., Ltd. and BrainsWay Ltd. jointly held the 2023 "International Symposium on Clinical Application of Deep Transcranial Magnetic Stimulation" from June 12 to 16. It was held successively in Shenzhen Mental Health Center (Shenzhen Kangning Hospital), the Second Xiangya Hospital of Central South University, Beijing Anding Hospital Affiliated to Capital Medical University, Peking University Sixth Hospital, the Mental Health Center Affiliated to Shanghai Jiaotong University School of Medicine and Huashan Hospital Affiliated to Fudan University.
The symposium invited Dr. Gaby Pell, chief physicist of BrainsWay, to give a keynote report. BrainsWay is the creator of DTMS technology and owns the global exclusive patent of DTMS. Currently, it has been approved by the FDA for the treatment of major depressive disorder, obsessive-compulsive disorder, smoking addiction, and anxious depression.
On the morning of June 12, as the strategic partner of YINGCHI, Dr. Gaby Pell, the chief physicist of BrainsWay, and Mr. Yossi Levental, the global sales director of BrainsWay came to Yingchi’s company for a visit and exchange. YINGCHI is a wholly-owned subsidiary of Hanix.
Group photo of YINGCHI leaders and BrainsWay experts
During the meeting, Mr. Xu Feng, the chairman of Shenzhen Yingchi Technology Co., Ltd., Dr. Gaby Pell and Mr. Yossi Levental from BrainsWay Ltd., discussed how to popularize deep transcranial magnetic stimulation technology in China and enable more patients to have a better treatment experience. A series of consensus has been reached. The discussion was very lively throughout the meeting and the atmosphere was at an all-time high.
After the meeting, Mr. Xu Feng showed the results of other products the company is developing to two experts from BrainsWay. Dr. Gaby Pell also personally experienced the conventional TMS of YINGCHI and gave it a high praise.
2017.4
YINGCHI and BrainsWay signed a strategic cooperation agreement to open the process of H coil localization!
2018.4
YINGCHI H1 deep coil (HF001A) obtained NMPA registration certificate!
2018.5
YINGCHI localization deep transcranial magnetic (DTMS) began to enter the Chinese market!
To date
YINGCHI & BrainsWay
4 FDA approvals!
(Major depressive disorder, Obsessive-compulsive disorder, Smoking addiction, Anxious depression)
Get 12 CE certification!
Developed 14 types of H coils!
Covers 30+ indications!
Contains 400+ high quality articles!
More than 1000 medical and scientific research users worldwide......
